Immunovant, Inc.

IMVT

$38.68

$-1.41 (-3.52%)

Open

Loading chart...

IndexN/A

Market Cap7.94B

Enterprise Value3.63B

Income$-0.41B

Sales$0.00B

EmployeesN/A

P/E-14.49

P/SN/A

P/B5.31

P/C-11.12

EV/EBITDA-7.19

EV/SalesN/A

EPS (ttm)-2.67

EarningsN/A

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Volume0.49M

Shs Outstand0.21B

Change-3.52%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Yesterday11:09PMImmunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy(seekingalpha.com)

Jul 2005:08PMKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm(globenewswire.com)

Jun 1912:31PMImmunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?(zacks.com)

Jun 1211:11AMImmunovant Stock Gains 12.4% in a Month: What's Driving It?(zacks.com)

May 2506:27AMImmunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential(seekingalpha.com)

May 2101:09PMRoivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy(seekingalpha.com)12:07PMThese Analysts Increase Their Forecasts On Immunovant After Q4 Results(benzinga.com)10:20AMIMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data(zacks.com)

May 2001:09PMImmunovant Stock Surges Despite Disappointing Earnings Miss(benzinga.com)10:08AMImmunovant Q4 Earnings Call Highlights(marketbeat.com)07:00AMImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026(globenewswire.com)

May 1104:05PMImmunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026(globenewswire.com)

Apr 2705:02AMImmunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock(defenseworld.net)

Apr 1104:14AMFinancial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)(defenseworld.net)

Apr 602:10PMIMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints(zacks.com)

Apr 401:05AMImmunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP(defenseworld.net)

Apr 204:32PMImmunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript(seekingalpha.com)05:06AMImmunovant's treatment for eye disease fails late-stage trial(reuters.com)05:00AMRoivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)(globenewswire.com)

Mar 1503:39PMA Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?(fool.com)

Mar 1112:48PMImmunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish(fool.com)

Mar 501:41PMImmunovant Stock Surges 17% in 3 Months: What's Driving It?(zacks.com)

Feb 1710:48AMSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)(prnewswire.com)

Feb 1001:16AMImmunovant (NASDAQ:IMVT) Hits New 12-Month High After Strong Earnings(defenseworld.net)

Feb 912:45PMIMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus(zacks.com)

Feb 601:24PMImmunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript(seekingalpha.com)07:00AMImmunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025(globenewswire.com)

Feb 210:55AMWall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know(zacks.com)

Jan 2305:25PMImmunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026(globenewswire.com)

Jan 1905:24AMSG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT(defenseworld.net)

Insider Trading

Insider

Type

Shares

Price

Value

Date

Option

1.5K

$8.43

$13K

Jul 24, 26

Sell

2.9K

$38.69

$111K

Jul 23, 26

Sell

6.8K

$38.69

$263K

Jul 23, 26

Sell

1.9K

$39.53

$75K

Jul 8, 26

Van Tuyl Christopher

Sell

1.1K

$39.53

$45K

Jul 8, 26

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

CEO: Eric VenkerEmployees: 315immunovant.com

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$21.00K	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	$-21.00K	N/A	N/A
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$438.15M	$270.21M	$208.28M	$156.03M	$108.12M	$59.66M	$450.00	$136.74M
Operating Income	$-438.15M	$-270.21M	$-208.28M	$-156.03M	$-108.12M	$-59.68M	$-450.00	$-136.74M
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-413.84M	$-259.34M	$-210.96M	$-156.73M	$-107.43M	$-66.39M	$-448.00	$-136.74M
Net Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-2.73	$-1.88	$-1.71	$-1.43	$-1.22	$-1.54	$-0.00	$-13.68
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Discover more

You may be interested in

Mastercard Inc

$561.47

Advanced Micro Devices

$456.66

Visa Inc

$370.84

Meta Platforms Inc

$594.18

Amazon.com Inc

$231.18

JPMorgan Chase & Co

$356.12

Salesforce Inc

$183.11

Netflix Inc

$73.11

IBM Corp

$228.28

Adobe Inc

$251.72

Intel Corp

$86.80

Bank of America Corp

$62.40